Global Autoinjectors Market Size study & Forecast, by Application (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, and Others), Type (Disposable Autoinjectors and Reusable Autoinjectors), End User (Home Care Settings, Hospital and Clinics, and Othe

Global Autoinjectors Market Size study & Forecast, by Application (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, and Others), Type (Disposable Autoinjectors and Reusable Autoinjectors), End User (Home Care Settings, Hospital and Clinics, and Others), and Regional Analysis, 2023-2030

Global Autoinjectors Market is valued approximately USD 8 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 16.05% over the forecast period 2023-2030. Autoinjectors are medical devices designed to deliver a single dose of a particular medication through a pre-filled syringe system. They are typically used by patients for self-administration of medications, particularly for conditions such as rheumatoid arthritis, multiple sclerosis, anaphylaxis, and other chronic diseases requiring regular injections. The market encompasses various types of autoinjectors, including manual and automated models, and serves healthcare providers, patients, and pharmaceutical companies seeking convenient and efficient drug delivery solutions. The market growth is driven by increasing Demand for Convenience of Patients, rising Incidence of Chronic and Lifestyle Diseases, technological Advancements.

For instance, As per the World Health Organization (WHO), the prevalence of chronic diseases is anticipated to increase by 57% by 2020 , with approximately 60% of this surge expected in emerging markets. Chronic diseases represent the foremost causes of disability and morbidity globally. According to the Globocan 2020 report, there were 19,292,789 new cancer cases diagnosed worldwide, resulting in 9,958,133 cancer-related deaths. Additionally, data from the International Diabetes Federation in December 2021 indicates that diabetes affects around 537 million adults aged 20 to 79. By 2030, the diabetic population is projected to reach 643 million, and by 2045, it is forecasted to climb to 783 million. Furthermore, according to various recent studies, a significant proportion of patients undergoing treatment for rheumatoid arthritis with an autoinjector reported comfort and even demonstrated improved outcomes compared to those relying on external administration. Moreover, market players' proactive initiatives are driving market expansion. For example, in March 2022, NORDIC PHARMA, a SEVER Life Sciences subsidiary, submitted a New Drug Submission to Health Canada for its methotrexate auto-injector, Nordimet, aimed at treating severe disabling active rheumatoid arthritis (RA) and providing symptomatic control of severe, recalcitrant, disabling psoriasis in adults unresponsive to alternative therapies. The anticipated approval of such medications is poised to accelerate market growth. However, preference for Alternative Drug Delivery Modes, and regulatory Hurdles stifle market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Autoinjectors Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America commands a substantial portion of the global disposable auto-injectors market throughout the forecast period, with expectations for being the fastest-growing region, closely trailed by APAC. The region's market dominance can be attributed to factors such as the early embrace of technologically advanced products, consistent product approvals, and the increasing incidence of chronic diseases, all of which contribute to market expansion.

Major market player included in this report are:
Dickinson and Company
Abbvie Inc
Amgen Inc.
AstraZeneca Plc
Bayer AG
Becton, Dickinson and Company
Biogen Inc
Eli Lilly and Company
Novartis AG
Teva Pharmaceuticals
Ypsomed AG
Abbvie
Amgen
AstraZeneca
Bayer
Becton
Biogen
Eli Lilly
Novartis
Teva Pharmaceuticals
Ypsomed

Recent Developments in the Market:
 In August 2023, Taisho Pharmaceutical obtained FDA approval to produce and distribute the Nanozora® 30 mg autoinjector, intended for treating patients with rheumatoid arthritis.
 In May 2023, Boehringer Ingelheim revealed FDA approval for the Cyltezo® Pen autoinjector, designed for patients with chronic inflammatory disorders.
 In May 2023, MoonLake partnered with SHL Medical to co-develop an autoinjector for the clinical and commercial distribution of MoonLake's Nanobody® sonelokimab.

Global Autoinjectors Market Report Scope:
 Historical Data – 2020 - 2021
 Base Year for Estimation – 2022
 Forecast period - 2023-2030
 Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
 Segments Covered – Type, Application, End-use, Region
 Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Type:
Rheumatoid Arthritis
Multiple Sclerosis
Anaphylaxis
Other Applications

By Application:
Disposable Autoinjectors
Reusable Autoinjectors

By End-use:
Home Care Settings
Hospital & Clinics
Other End Users
By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.